Decoding Glycemic Control in Dialysis: Why HbA1c and Glycated Albumin Require a Nuanced Approach
Posted inDiabetes & Endocrinology Nephrology news

Decoding Glycemic Control in Dialysis: Why HbA1c and Glycated Albumin Require a Nuanced Approach

This study evaluates HbA1c, glycated albumin, and fructosamine against CGM in dialysis patients. While HbA1c and glycated albumin show strong correlations with mean glucose, significant clinical biases from ESA use, BMI, and dialysis modality necessitate cautious, individualized interpretation in clinical practice.
Spironolactone Versus Placebo in Maintenance Dialysis Patients: Insights from the ACHIEVE Trial and Contemporary Evidence
Posted inClinical Updates Nephrology Specialties

Spironolactone Versus Placebo in Maintenance Dialysis Patients: Insights from the ACHIEVE Trial and Contemporary Evidence

This review consolidates evidence from the ACHIEVE trial and related studies evaluating spironolactone's efficacy and safety in patients undergoing maintenance dialysis, highlighting lack of cardiovascular benefit and discussing future directions for mineralocorticoid receptor antagonism in this population.